Combined Use of Duloxetine and Olanzapine in the Treatment of Urologic Chronic Pelvic Pain Syndromes Refractory to Conventional Treatment: A Case Report

Bi, Bo; Shan, Liping; Zhou, Die

doi:10.9758/cpn.2018.16.1.122

Cited by 3 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, antidepressant drugs have indirect effects on opioid, histamine, 5-serotonin and other receptors that produce an analgesic effect (Sawynok et al, 2001). Duloxetine is a serotoninnorepinephrine reuptake inhibitor that was shown to improve UCCPS symptoms when used alone or in combination with other treatments (Bi et al, 2018;Giannantoni et al, 2014;M. Zhang et al, 2017).…”

Section: Botulinum Toxin a (Botn-a) Injections In The Urinary Bladder...mentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic Approaches for Urologic Chronic Pelvic Pain Syndrome; Management: Research Advances, Experimental Targets, and Future Directions

Ashraf,

Clarkson,

Malykhina

2024

J Pharmacol Exp Ther

View full text Add to dashboard Cite

Urologic Chronic Pelvic Pain Syndrome (UCPPS) is a painful chronic condition with persistent pain originating from the pelvis that often leads to detrimental lifestyle changes in the affected patients. The syndrome develops in both sexes, with an estimated prevalence of 5.7% to 26.6% worldwide. This narrative review summarizes currently recommended therapies for UCPPS, followed by the latest animal model findings and clinical research advances in the field. The diagnosis of UCPPS by clinicians has room for improvement despite the changes in the past decade aiming to decrease the time to treatment. Therapeutic approaches targeting growth factors (i.e., NGF, VEGF), amniotic bladder therapy and stem cell treatments gain more attention as experimental treatment options for UCPPS. The development of novel diagnostic tests based on the latest advances in urinary biomarkers would be beneficial to assist with the clinical diagnosis of UCPPS. Future research directions should address the role of chronic psychological stress and the mechanisms of pain refractory to conventional management strategies in UCPPS etiology. Testing the applicability of cognitive behavioral therapy in this cohort of UCPPS patients might be promising to increase their QoL. The search for novel lead compounds and innovative drug delivery systems requires clinically relevant translational animal models. The role of autoimmune responses triggered by environmental factors is another promising research direction to clarify the impact of the immune system in UCPPS pathophysiology. SIGNIFICANCE STATEMENTThis minireview provides an up-to-date summary of the therapeutic approaches for UCPPS with focus on recent advancements in the clinical diagnosis and treatments of the This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward.

show abstract

Section: Botulinum Toxin a (Botn-a) Injections In The Urinary Bladder...mentioning

confidence: 99%

“…Treat underlying psychosocial conditions Bi et al, 2018;Cakici et al, 2018;Engel et al, 1998;Giannantoni et al, 2014;Hertle & van Ophoven, 2010;Lee et al, 2005;van Ophoven & Hertle, 2005;van Ophoven et al, 2004;M. Zhang et al, 2017…”

Section: Syndromeunclassified

Therapeutic Approaches for Urologic Chronic Pelvic Pain Syndrome; Management: Research Advances, Experimental Targets, and Future Directions

Ashraf,

Clarkson,

Malykhina

2024

J Pharmacol Exp Ther

View full text Add to dashboard Cite

show abstract

“…5 CP/CPPS is characterized by persistent discomfort experienced in the perineum, penile tip, suprapubic region, or scrotum, often exacerbated during urination or ejaculation. 6 Although CP/CPPS is not life-threatening, the persistent and long-lasting pain it brings about can severely affect the quality of life for those affected. 7 Multiple theories have been proposed to explain the underlying causes of CP/CPPS, including notions of chronic inflammation/autoimmunity, dysfunction within the pelvic floor muscles, and concealed infections.…”

Section: Introductionmentioning

confidence: 99%

“…Notably, the majority of prostatitis cases (90%–95%) fall under the classification of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) (NIH‐III) 5 . CP/CPPS is characterized by persistent discomfort experienced in the perineum, penile tip, suprapubic region, or scrotum, often exacerbated during urination or ejaculation 6 . Although CP/CPPS is not life‐threatening, the persistent and long‐lasting pain it brings about can severely affect the quality of life for those affected 7 .…”

Section: Introductionmentioning

confidence: 99%

Hedyotis diffusa Willd inhibits inflammation and oxidative stress to protect against chronic prostatitis via the NRF2/ARE signaling pathway

Mo,

Xia,

2024

Environmental Toxicology

View full text Add to dashboard Cite

Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) is a common and serious disease with unclear pathogenesis and recurrent symptoms. Hedyotis diffusa Willd (HDW) has been recognized for its potential in managing various chronic inflammatory diseases. This research aimed to interrogate the mechanism of HDW in treating CP/CPPS. Complete Freund Adjuvant (CFA) and LPS were utilized to establish the rat and cell models of CP/CPPS. Results showed that HDW decreased levels of inflammation‐related factors in CP rat prostate tissue and LPS‐elicited RWPE‐1 cell injury model. Moreover, HDW administration impaired oxidative stress in the prostate and RWPE‐1 cells. In addition, HDW treatment activated the NRF2/ARE signaling in rat prostate tissue and cell models. Interestingly, NRF2/ARE pathway inhibitor ML385 reversed the inhibition effects of cell apoptosis, inflammation, and oxidative stress triggered by HDW. In summary, HDW alleviated inflammation and oxidative stress by activating NRF2/ARE signaling in CP/CPPS rat model and human prostate epithelial cell injury model.

show abstract

The Benefits of Olanzapine in Palliating Symptoms

Davis

Sanger

2020

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Opinion statementOlanzapine has become a major drug in the management of chemotherapy-induced nausea and vomiting as a prophylactic agent. In addition, a recent randomized trial has demonstrated its benefits in treating nausea and vomiting associated with advanced cancer. The added benefit to olanzapine is that it also stimulates appetite. As a result, since it treats multiple symptoms associated with advanced cancer, it is likely to become the antiemetic of choice in palliative care at least in the United States. The added benefit of treating insomnia and the avoidance of benzodiazepines should place olanzapine in at the top of the list of drugs to use for patients who do complain of insomnia. There is no good evidence that it potentiates the respiratory depression of opioids unlike benzodiazepines. The evidence is weak that olanzapine in as an adjuvant analgesic. Hopefully, future trials will explore this in greater depth. The benefits of adding olanzapine to potent opioids is that it may reduce craving, drug cues and opioid misuse. Other symptoms like anxiety and depression may be addressed by the addition of olanzapine to standard antidepressants.

show abstract

Combined Use of Duloxetine and Olanzapine in the Treatment of Urologic Chronic Pelvic Pain Syndromes Refractory to Conventional Treatment: A Case Report

Cited by 3 publications

References 25 publications

Therapeutic Approaches for Urologic Chronic Pelvic Pain Syndrome; Management: Research Advances, Experimental Targets, and Future Directions

Therapeutic Approaches for Urologic Chronic Pelvic Pain Syndrome; Management: Research Advances, Experimental Targets, and Future Directions

Hedyotis diffusa Willd inhibits inflammation and oxidative stress to protect against chronic prostatitis via the NRF2/ARE signaling pathway

The Benefits of Olanzapine in Palliating Symptoms

Contact Info

Product

Resources

About